AMAG wins FDA nod for Vyleesi. Could it be the ‘female Viagra’ that Addyi never was?
Valeant, now Bausch Health, paid $ 1 billon in 2015 for Sprout Pharmaceuticals’ female libido drug Addyi, only to sell it back in 2017. Now as the drug is still nowhere near the blockbuster status Valeant once touted, a rival has arrived. The FDA late Friday approved AMAG Pharmaceuticals’ Vyleesi (bremelanotide) to treat premenopausal women with… Read More »